Neuren Pharmaceuticals Limited

Australia

Create a watch for Neuren Pharmaceuticals Limited
Total IP 11
Total IP Rank # 142,603
IP Activity Score 0/5.0    0
IP Activity Rank # 1,707,733
Stock Symbol NEU (asx)
ISIN NZNEUE0001S8
Market Cap. 1.7B  (AUD)
Industry Biotechnology
Sector Healthcare

Patents

Trademarks

10 0
1 0
0 0
0
 
Last Patent 2014 - Treatment of fragile x syndrome ...
First Patent 2002 - Gpe analogs and peptidominetics

Latest Inventions, Goods, Services

2012 Invention Oral formulations of glycyl-2-methylprolyl-glutamate. Oral formulations of G-2MePE including micr...
Invention Treatment of fragile x syndrome using glycyl-l-2-methylprolyl-l-glutamate. This invention provide...
2011 Invention Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals. Embodiments of ...
2010 Invention Cognitive enhancement and cognitive therapy using glycyl-l-2-methylprolyl-l-glutamic acid. This i...
Invention Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy. Embodiments of t...
2007 Invention Substituted pyrrolo[1,2-d][1,4]-diazonines and treatment of brain damage. Embodiments of this inv...
Invention Analogs of glycyl-prolyl-glutamate. Embodiments of this invention include novel analogs of Glycyl...
2006 Invention Cyclic g-2allylproline in treatment of parkinson's disease. Embodiments of this invention provide...
Invention Treatment of non-convulsive seizures in brain injury using g-2-methyl-prolyl glutamate. Aspects o...
2005 Invention Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration. This invention provides analogs...
2004 Invention Neuroprotective bicyclic compounds and methods for their use. Embodiments of this invention provi...
Invention Neuroprotective macrocyclic compounds and methods for their use. Embodiments of this invention pr...
2002 Invention Gpe analogs and peptidominetics. This invention relates to analogs and peptidomimetics of glycyl-...